Canopy Growth

Canopy Growth reported Q1 fiscal 2027 revenue of $58.9 million, up 13% year-over-year, with adjusted gross margin improving to 31% and adjusted EBITDA loss narrowing to $2.3 million. The company still recorded a net loss of $10.6 million and free cash outflow widened to $18.6 million, while some sales growth reflected the MTL Cannabis acquisition rather than pure organic expansion. Investors remained cautious given years of cash burn, restructuring and share issuance; management must demonstrate sustained revenue growth, margin gains and falling cash burn before markets reward the stock. » Mere på finance.yahoo.com

Canopy Growth has received renewed EU‑GMP certification for its production site in Kincardine, Ontario, from the Regierungspräsidium Tübingen. The certification continues to allow shipments of Canada‑grown medical cannabis from Kincardine to European markets and, together with the EU‑GMP facility in Sankt Leon‑Rot, Germany, strengthens the supply chain. The company reported international net revenue growth in its cannabis business of 10% year‑over‑year for Q1 of fiscal 2027 and plans to expand its flower portfolio for patients in Europe. » Mere på de.investing.com

Canopy Growth presented a turnaround plan at a growth conference focused on better cultivation, strict cost control and intensified expansion in Europe. The company reported Q1 2027 revenue growth of 13% (Europe +10%) and cut costs by more than CAD 30m, lifting gross margin to 31% (+600 basis points). Canopy is targeting a run-rate in Europe of CAD 100–150m (currently ~CAD 40m) and is concentrating on the Canadian market as well as Germany, Poland and the UK, supported by the acquisition of MTL, EU‑GMP certification and a shift to indoor cultivation. » Mere på de.investing.com